PharmaCyte Biotech (PMCB) EBT (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly EBT of -$21.8 million for Q2 2026, down 35.97% year-over-year from -$34.0 million in Q2 2025, and down 1055.03% quarter-over-quarter from -$1.9 million in Q1 2026.
PharmaCyte Biotech (PMCB) EBT (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported EBT for 17 consecutive years, with -$21.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT fell 35.97% year-over-year to -$21.8 million; the TTM figure through Apr 2026 stood at -$25.5 million (down 40.17% YoY), while the FY2026 annual figure was -$25.5 million, down 40.17% from the prior year.
- EBT declined to -$21.8 million in Q2 2026 per PMCB's latest filing, from -$1.9 million in the prior quarter.
- Across five years, EBT topped out at -$180346.0 in Q2 2023 and bottomed at -$21.8 million in Q2 2026.
- Historically, EBT has averaged -$3.9 million across 5 years, with a median of -$1.1 million in 2024.
- Annual changes were most pronounced in 2023 — EBT soared 87.31% — and 2024, when it sank 9666.14%.
- PharmaCyte Biotech's EBT stood at -$1.9 million in 2022, then jumped by 72.61% to -$515339.0 in 2023, then tumbled by 40.39% to -$723498.0 in 2024, then plunged by 61.67% to -$1.2 million in 2025, then sank by 1763.81% to -$21.8 million in 2026.
- Business Quant data shows PMCB's EBT at -$21.8 million in Q2 2026, -$1.9 million in Q1 2026, and -$1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | PharmaCyte Biotech | 4.30 Mn | 4.30 Mn | - | -2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -21.80 Mn |
| Jan 31, 2026 | -1.89 Mn |
| Oct 31, 2025 | -1.17 Mn |
| Jul 31, 2025 | -630,512.00 |
| Apr 30, 2025 | -16.03 Mn |
| Jan 31, 2025 | -704,560.00 |
| Oct 31, 2024 | -723,498.00 |
| Jul 31, 2024 | -721,455.00 |
| Apr 30, 2024 | -17.61 Mn |
| Jan 31, 2024 | -987,284.00 |
| Oct 31, 2023 | -515,339.00 |
| Jul 31, 2023 | -1.20 Mn |
| Apr 30, 2023 | -180,346.00 |
| Jan 31, 2023 | -912,130.00 |
| Oct 31, 2022 | -1.88 Mn |
| Jul 31, 2022 | -1.55 Mn |
| Apr 30, 2022 | -1.42 Mn |
| Jan 31, 2022 | -814,913.00 |
| Oct 31, 2021 | -986,104.00 |
| Jul 31, 2021 | -1.02 Mn |